Diabetes drug empagliflozin tested in 230,000 patients in Real-World study
NCT ID NCT03363464
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This study looks at how well the diabetes drug empagliflozin (Jardiance) works in everyday medical practice, outside of a controlled research setting. Researchers are comparing it to other diabetes medications in over 230,000 adults with type 2 diabetes. The goal is to see if the heart and kidney benefits shown in earlier trials hold true for a wider, more diverse patient group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bringham Women Hospital
Boston, Massachusetts, 02120, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Empagliflozin (also known as Jardiance)
What this could lead to
If successful, this study could confirm that empagliflozin's heart and kidney benefits seen in clinical trials also apply to a broader, real-world population with type 2 diabetes.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors other than the drug. It also relies on insurance claims data, which may miss some details.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.